Nasdaq:US$13.49 (-0.19) | HKEX:HK$21.16 (-0.16) | AIM:£2.15 (+0)
Search
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Regulatory Notice | 12 May 2026

Annual General Meeting held on May 12, 2026 – Poll Results

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 12, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting (“AGM”) held on May 12, 2026 were duly passed. The poll results of the resolutions were as follows:

 

Ordinary Resolutions Number of Votes (%)* Passed by Shareholders
For  Against  Withheld# 
1. To consider and adopt the audited Financial Statements, and the Directors’ Report and the Independent Auditors’ Report for the year ended December 31, 2025. 440,149,560
(99.9998%)		 1,020
(0.0002%)		 36,866 Yes
2(A). To re-elect Dr Dan ELDAR as a Director. 409,558,086
(93.0477%)		 30,601,245
(6.9523%)		 26,615 Yes
2(B). To re-elect Dr Weiguo SU as a Director. 413,398,701
(93.9185%)		 26,768,655
(6.0815%)		 18,590 Yes
2(C). To re-elect Mr CHENG Chig Fung, Johnny as a Director. 410,525,379
(93.2657%)		 29,642,001
(6.7343%)		 18,566 Yes
2(D). To re-elect Ms Edith SHIH as a Director. 426,101,060
(96.8043%)		 14,066,301
(3.1957%)		 18,585 Yes
2(E). To re-elect Ms Ling YANG as a Director.

428,114,519

(97.2618%)

 12,052,842
(2.7382%)		 18,585 Yes
2(F). To re-elect Dr Renu BHATIA as a Director. 436,786,545
(99.2319%)		 3,380,786
(0.7681%)		 18,615 Yes
2(G). To re-elect Dr Chaohong HU as a Director. 440,122,580
(99.9898%)		 44,806
(0.0102%)		 18,560 Yes
2(H). To re-elect Professor TAN Shao Weng, Daniel as a Director. 440,141,241
(99.9941%)		 26,130
(0.0059%)		 18,575 Yes
2(I). To re-elect Mr WONG Tak Wai as a Director. 440,128,120
(99.9911%)		 39,265
(0.0089%)		 18,561 Yes
3. To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as Independent Auditors for Hong Kong financial reporting and US financial reporting purposes, respectively, and to authorize the Directors to fix the Auditors’ remuneration. 394,937,813
(89.7296%)		 45,204,596
(10.2704%)		 43,537 Yes
Special Resolution
4. To grant a general mandate to the Directors to issue additional shares of the Company.^ 440,097,496
(99.9851%)		 65,548
(0.0149%)		 22,902 Yes
Ordinary Resolution
5. To grant a general mandate to the Directors to repurchase shares of the Company.^ 440,120,461
(99.9933%)		 29,603
(0.0067%)		 35,382 Yes
6. To approve the adoption of 2026 Share Option Scheme of the Company.^ 396,856,980
(90.1613%)		 43,306,320
(9.8387%)		 22,146 Yes

 

*  Percentages rounded to 4 decimal places.

# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.

^ The full text of Resolutions 4, 5 and 6 are set out in the notice of AGM dated April 10, 2026.

 

Notes:

  • All directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Ms Ling YANG, Professor MOK Shu Kam, Tony, Dr Renu BHATIA, Dr Chaohong HU, Professor TAN Shao Weng, Daniel and Mr WONG Tak Wai, attended the AGM, either in person or by means of electronic facilities.

  • Number of shares entitling the holders to attend and vote on the resolution at the AGM: [872,335,120] shares.

  • Number of shares entitling the holders to attend and abstain from voting in favor as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) at the AGM: Nil.

  • Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil.

  • The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

2 items
LSE RNS Announcement (PDF)HKEX Announcement (PDF)